Banque Transatlantique Sa Akebia Therapeutics, Inc. Transaction History
Banque Transatlantique Sa
- $5.69 Billion
- Q1 2025
A detailed history of Banque Transatlantique Sa transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Banque Transatlantique Sa holds 2,250 shares of AKBA stock, worth $6,435. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,250Holding current value
$6,435% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
157Shares Held
96.8MCall Options Held
98.6KPut Options Held
320K-
Vanguard Group Inc Valley Forge, PA12.7MShares$36.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$33.3 Million0.0% of portfolio
-
State Street Corp Boston, MA6.81MShares$19.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$16.4 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA5.03MShares$14.4 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $526M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...